FDA Issues Warning Letter to 3D Imaging Drug Design & Development
December 17, 2025
December 17, 2025
WASHINGTON, Dec. 17 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to 3D Imaging Drug Design and Development LLC from the Center for Drug Evaluation and Research:
* * *
Recipient: Marc S. Berridge, Ph.D., President, 3D Imaging Drug Design and Development LLC, 9015 Carti Way, Little Rock, AR 72205, United States
Issuing Office: Center for Drug Evaluation and Research (CDER), United States< . . .
* * *
Recipient: Marc S. Berridge, Ph.D., President, 3D Imaging Drug Design and Development LLC, 9015 Carti Way, Little Rock, AR 72205, United States
Issuing Office: Center for Drug Evaluation and Research (CDER), United States< . . .
